Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis-Reference-Cited by-同舟云学术

Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis

Published:2017-07-27 Issue:1 Volume:11 Page:63-70
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Conrado Daniela J.¹,Nicholas Timothy²,Tsai Kuenhi³,Macha Sreeraj³,Sinha Vikram³,Stone Julie³,Corrigan Brian²,Bani Massimo⁴,Muglia Pierandrea¹,Watson Ian A.⁵,Kern Volker D.¹,Sheveleva Elena¹⁶,Marek Kenneth⁷,Stephenson Diane T.¹,Romero Klaus¹,

Affiliation:

1. Critical Path Institute; Tucson Arizona USA

2. Pfizer Inc; Groton Connecticut USA

3. Merck Sharp & Dohme; North Wales Pennsylvania USA

4. UCB; Brussels Belgium

5. Eli Lilly; Indianapolis Indiana USA

6. University of Arizona; Tucson Arizona USA

7. Institute for Neurodegenerative Disorders; New Haven Connecticut USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12492/fullpdf

Reference20 articles.

1. Parkinson's disease;Kalia;Lancet,2015

2. The epidemiology of Parkinson's disease: risk factors and prevention;Ascherio;Lancet Neurol,2016

3. American Academy of Neurology Compelling Statistics. [Internet]. https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/6.Public_Policy/1.Stay_Informed/4.Public_Policy_Resources/compell.pdf

4. Pharmacological treatment of Parkinson disease: a review;Connolly;JAMA,2014

5. Longitudinal follow-up of SWEDD subjects in the PRECEPT study;Marek;Neurology,2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Developing disease-modifying interventions in idiopathic REM sleep behavior disorder and early synucleinopathy;Parkinsonism & Related Disorders;2024-08

2. Reduction in variability of dopamine transporter measures using SPECT and ultra-high-resolution fan beam collimators: comparison with parallel-hole collimators in healthy controls for a clinical reference database;Clinical and Translational Imaging;2024-02-24

3. Prognostic biomarkers in prodromal α-synucleinopathies: DAT binding and REM sleep without atonia;Journal of Neurology, Neurosurgery & Psychiatry;2023-02-01

4. Leveraging the regulatory framework to facilitate drug development in Parkinson's disease;Handbook of Clinical Neurology;2023

5. The dilemma between milestones of progression versus clinical scales in Parkinson's disease;Precision Medicine in Neurodegenerative Disorders, Part I;2023